X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - ZACKS.COM - All Stories - 15/Aug 10:25

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

Articles similaires

Sorry! Image not available at this time

Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

zacks.com - 04/Sep 14:51

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

Sorry! Image not available at this time

Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

zacks.com - 04/Sep 14:51

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

Sorry! Image not available at this time

MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate

zacks.com - 28/Aug 16:46

Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood...

Sorry! Image not available at this time

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

zacks.com - 15:27

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

Sorry! Image not available at this time

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

drugs.com - 08/Sep 06:09

September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...

Sorry! Image not available at this time

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

drugs.com - 08/Sep 06:09

September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...

Sorry! Image not available at this time

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

zacks.com - 04/Sep 15:32

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Sorry! Image not available at this time

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

zacks.com - 04/Sep 15:32

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Sorry! Image not available at this time

Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More

zacks.com - 06/Sep 13:45

European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...

Sorry! Image not available at this time

RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study

zacks.com - 10/Sep 14:44

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

Les derniers communiqués